Neil Kanth Taunk, MD/MS

---

---

Description of Research Expertise

My research falls into three broad categories 1) development and translation of novel molecular imaging agents primarily PET tracers and radiopharametical therapy agents 2) imaging radiation treatment response include imaging biomarkers and radiogenomic analysis and 3) clinical trials in breast, gynecologic, and prostate cancers to improve therapeutic ratio. I work establish interdisciplinary collaborations with radiology, medical physics, and the clinical teams in medical and surgical oncology.

Description of Clinical Expertise

My research falls into three broad categories 1) development and translation of novel molecular imaging agents primarily PET tracers 2) imaging radiation treatment response include imaging biomarkers and radiogenomic analysis and 3) clinical trials in breast, gynecologic, and prostate cancers to improve therapeutic ratio. I work establish interdisciplinary collaborations with radiology, medical physics, and the clinical teams in medical and surgical oncology.

Selected Publications

• Smith EE, Heintz JR, Chesnokova A, Taunk NK. : Improving Treatment of Radiation-Induced Premature Ovarian Insufficiency After Cervical Cancer: A Practice Quality Improvement Initiative Int J Radiat Oncol Biol Phys 126 : 48-54, Sep 2026
• Wright JL, Ko K, Kenworthy W, Bosch W, Straube W, Zou W, Remmes N, Pankuch M, Berlin E, Berrington de Gonzalez A, Boggs DH, Braunstein LZ, Cahlon O, Chawla A, Croog V, Fagundes M, Fang LC, Feriozzi A, Freedman GM, Gillespie EF, Hoffman K, Jimenez RB, Kim J, Lu HL, MacDonald S, Meier T, Mishra M, Mutter R, Ohri N, Pugh SL, Rosen L, Taghian A, Taunk N, Thukral AD, Urbanic J, Bekelman JE, Lin A, Ky B; RadComp Consortium. : Associations Between Cardiac Radiation Dose-Volume Metrics and Health-Related Quality of Life for Patients With Breast Cancer on the RadComp Trial Int J Radiat Oncol Biol Phys Jul 2026
• Mulugeta PG, O'Brien SR, Mankoff DA, Sartor O, Taunk NK. : A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT J Nucl Med 67 : 1172-1173, Jul 2026
• Atobiloye M, Howell J, Cruttenden J, Weil C, Taunk N, Suneja G, Gaffney D, Burt L, DeCesaris C. : Improved Overall Survival Associated With Vaginal Cuff Brachytherapy Boost for Stage II Endometrioid Endometrial Cancer Adv Radiat Oncol 11 : 102124, Jun 2026
• Pepin A, Doucette A, Narayan VK, Maxwell KN, Takvorian SU, O'Brien SR, Mankoff DA, Mulugeta PG, Taunk NK. : Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer J Nucl Med 67 : 926-928, Jun 2026
• Khan S, Olsen TC, Voytik M, Sun F, Riina MD, Broach RB, Hsu JY, Freedman GM, Taunk NK, Azoury SC. : The Relationship of Radiation Therapy Parameters and Perioperative Morbidity and Toxicities on Breast Reconstruction Outcomes Ann Plast Surg 96 : S319-S325, May 2026
• Howell JN, Wilkes J, Maughan NM, Patel RB, Barney B, Taunk NK, Escorcia FE, Johnson SB, Boothe D. : Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade Int J Radiat Oncol Biol Phys 124 : 575-580, Mar 2026
• Go AE, Feliciano EJG, Martinez J, Ho FDV, Wu JF, Willmann J, Lapen K, Hugo H, Jeong Y, Singh A, Haylock AB, Shah N, Robredo JPG, Eala MAB, Patel RK, Chen J, Cabaero MLL, Tawfiles D, Venkateswaran S, Tan AKNG, Gyawali B, Moraes FY, Iyengar P, Lee NY, Mango VL, Taunk NK, Magsanoc-Alikpala MJK, Kingham TP, Dee EC. : Global determinants of cervical cancer outcomes: a health systems analysis BMJ Oncol 5 : e000975, Jan 2026
• Pepin A, Almeida ND, Fung-Kee-Fung S, Kassick M, Taunk NK, Freedman GM. : Boost Approaches in Patients Undergoing Postoperative Radiotherapy J Surg Oncol 2026
• O'Brien SR, Pantel AR, Taunk N, Mankoff D, Gray D, Mulugeta P. : Creating a dedicated radionuclide therapy clinic and leveraging telemedicine to increase access to radiopharmaceutical therapies Clin Imaging 2026